Stockreport

Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women

Atossa Therapeutics, Inc.  (ATOS) 
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.atossagenetics.com
PDF SEATTLE, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery me [Read more]